Semaglutide is the active ingredient in three of the most prescribed drugs of the past decade: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management. It is a peptide, an engineered analogue of a human hormone, and it has been through some of the largest cardiovascular and weight-loss trials ever run. That makes it an unusual entry on a peptide site. Most compounds we cover have thin published evidence. This one has the opposite problem.
What it is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Novo Nordisk. GLP-1 is an incretin hormone the gut releases after eating; it nudges the pancreas to put out insulin, tamps down glucagon, slows how fast the stomach empties, and signals fullness to the brain.
The molecule shares about 94% of its sequence with native human GLP-1. Two changes do the heavy lifting. A substitution at position 8 (alanine swapped for 2-aminoisobutyric acid) blocks the enzyme DPP-4 from chewing it up, and a C18 fatty diacid chain attached at lysine 26 (via a spacer) makes it bind tightly to blood albumin. That albumin binding is why it lingers: the elimination half-life is roughly one week, which is what allows once-weekly injection (StatPearls / NCBI Bookshelf).
Regulatory status
Semaglutide is an FDA-approved prescription drug, not a research chemical. The approvals came in stages:
- Ozempic (subcutaneous), 2017, for type 2 diabetes, later expanded to reduce cardiovascular events in patients with established heart disease.
- Rybelsus (oral tablet), 2019, the first GLP-1 available as a pill.
- Wegovy (higher-dose subcutaneous), 2021, for chronic weight management.
It carries a boxed warning for thyroid C-cell tumors, based on rodent data, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 (StatPearls).
What the trials show
The evidence base is large and the headline results are consistent. The clearest cardiovascular signal comes from SELECT, a randomized, double-blind, placebo-controlled trial of 17,604 adults who had overweight or obesity and established cardiovascular disease but not diabetes. Semaglutide cut major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% versus placebo (6.5% vs 8.0%; hazard ratio 0.80, 95% CI 0.72–0.90) over roughly three years (American College of Cardiology trial summary; full results in the SELECT analyses in Nature Medicine). The same population lost about 10% of body weight on average against 1.5% on placebo.
Gastrointestinal side effects are common rather than rare. Nausea, vomiting, and diarrhea show up in a large share of users, and nausea alone was reported in roughly 44% of Wegovy patients in trials. Less common but more serious concerns include gallbladder disease and acute kidney injury, usually tied to dehydration from vomiting (StatPearls).
WADA status
For athletes this matters. GLP-1 receptor agonists, semaglutide included, were on WADA's Monitoring Program from 2024 (tracked but not banned). For 2026 the picture has shifted toward prohibition, so anyone in tested sport should check the current WADA Prohibited List directly rather than rely on last season's rules.
The quality and counterfeit angle
Because demand outran supply, semaglutide became a target for counterfeiting and questionable compounding, and this is where buyer caution is warranted. In April 2025 the FDA was notified of several hundred units of counterfeit Ozempic in the legitimate U.S. supply chain. Separately, the FDA has logged hundreds of adverse-event reports tied to compounded semaglutide, many from dosing errors when people draw from multidose vials, and some products turned out to contain salt forms (semaglutide sodium, semaglutide acetate) that have not been shown to be safe or effective (FDA counterfeit Ozempic alert).
The practical takeaway for anyone evaluating a source: identity and purity are not a given for material sold outside the brand-name, FDA-regulated channel. A certificate of analysis confirming the correct base form, identity, and purity is the kind of third-party documentation that separates a legitimate product from a counterfeit or an off-spec salt.
This page aggregates public information and is not medical or dosing advice. Semaglutide sold as research material is not the same as the FDA-approved prescription product, and unapproved or compounded versions carry documented identity and safety risks. Always defer to a clinician and to current regulatory guidance.